Biogen Option Alert: Jan, 2027 $115 Puts at the Bid: 450 vs 30 OI

Biogen Option Alert: Jan, 2027 $115 Puts at the Bid: 450 @ $13.6 vs 30 OI; Ref=$136.2

Biogen Option Alert: Jan, 2027 $115 Puts at the Bid: 1000 vs 30 OI

Biogen Option Alert: Jan, 2027 $115 Puts at the Bid: 1000 @ $13.6 vs 30 OI; Ref=$136.005

Biogen (NASDAQ:BIIB) 株価情報

Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biotech

Earnings

News

Guidance

Health Care

Movers

General

BIIB

米国バイオテクノロジー大手（BIIB）バイオジェン（Biogen Inc）が、2022年第2四半期の調整後1株当たり利益（EPS）を前年同期比31％増の5.28ドル（約607円）と発表し、コンセンサス予想の4.03ドルを上回ったと見られている。

米テクノロジー大手　バイオジェン　コンセンサス予想上回る

Biogen Inc

Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BIIB usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Biogen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 36% leaning bullish and 27% bearish. Among these notable options, 3 are puts, totaling $154,362, and 8 are calls, amounting to $325,022.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $120.0 to $155.0 for Biogen over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Biogen's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Biogen's whale trades within a strike price range from $120.0 to $155.0 in the last 30 days. 
<h3>Biogen Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740159930_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$9.7</td>
<td>$9.5</td>
<td>$9.7</td>
<td>$135.00</td>
<td>$72.7K</td>
<td>479</td>
<td align="right">1</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$5.3</td>
<td>$5.1</td>
<td>$5.2</td>
<td>$140.00</td>
<td>$52.0K</td>
<td>122</td>
<td align="right">113</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$20.5</td>
<td>$19.9</td>
<td>$20.5</td>
<td>$120.00</td>
<td>$51.2K</td>
<td>1.0K</td>
<td align="right">115</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$9.7</td>
<td>$9.6</td>
<td>$9.7</td>
<td>$150.00</td>
<td>$49.4K</td>
<td>119</td>
<td align="right">3</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$12.6</td>
<td>$11.9</td>
<td>$12.3</td>
<td>$130.00</td>
<td>$49.2K</td>
<td>149</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Biogen</h3>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Having examined the options trading patterns of Biogen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Biogen Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 601,076, the BIIB's price is up by 2.28%, now at $140.21. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 61 days.</li>
</ul>
<h3>Professional Analyst Ratings for Biogen</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $170.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Outperform rating for Biogen, targeting a price of $224. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Biogen with a target price of $145. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Biogen with a target price of $210. 
&#x2A; An analyst from BMO Capital persists with their Market Perform rating on Biogen, maintaining a target price of $139. 
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $135.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Biogen options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

Biogen Options Trading: A Deep Dive into Market Sentiment

On Tuesday, Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)&nbsp;and&nbsp;Stoke Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>)&nbsp;collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43778917/biogen-and-stoke-therapeutics-enter-into-collaboration-to-develop-and-commercialize-zorevunersen-f" rel="noreferrer noopener">United States, Canada, and Mexico</a>.
Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the&nbsp;SCN1A gene, the underlying cause of most cases of Dravet syndrome.
Stoke recently announced plans to initiate a global Phase 3 registrational study of zorevunersen (EMPEROR) following the alignment with regulatory agencies in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42840166/stoke-therapeutics-announces-alignment-with-global-regulatory-agencies-and-plans-to-initiate-a-pha" rel="noreferrer noopener">United States, Europe, and Japan</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43708416/leqembi-and-skyclarys-expected-to-drive-biogens-future-growth" rel="noreferrer noopener">Leqembi And Skyclarys Expected To Drive Biogen&#8217;s Future Growth: Analysts</a>
The study is on track to initiate in the second quarter of 2025, with a pivotal data readout expected in the second half of 2027, which is anticipated to support global regulatory filings.
Stoke will continue to lead global development and retain exclusive development and commercialization rights for zorevunersen in the U.S., Canada, and Mexico.
Biogen receives exclusive rights to commercialize zorevunersen in the rest of the world. Stoke will receive an upfront payment of $165 million. The parties will share external clinical development costs for zorevunersen (30% Biogen; 70% Stoke).
Additionally, Stoke may receive up to $385 million in development and commercial milestone payments.
Stoke will also be eligible to receive tiered royalties on potential net sales in the Biogen territory, ranging from low double digits to high teens.
Stoke has also granted Biogen an option to license rights outside of the U.S., Canada, and Mexico to certain future follow-on ASO products targeting&nbsp;SCN1A, in exchange for separate milestone, cost sharing, and royalty considerations.
&#8220;Additionally, this collaboration provides cash flows, that when combined with Stoke&#8217;s financial position, support the company through to mid-2028,&#8221; said Edward Kaye, CEO of Stoke Therapeutics.
Price Action: At last check Tuesday, BIIB was down 0.79% at $136.24, and STOK was down 3.15% at $10.34.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/25/02/43778605/tesla-files-fresh-lawsuit-against-matthews-after-court-defeat" target="_blank" rel="noreferrer noopener">Tesla Files Fresh Lawsuit Against Matthews After Court Defeat</a></li>
</ul>

Large Cap

Contracts

STOK

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

Piper Sandler analyst Christopher Raymond reiterates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Neutral and lowers the price target from $138 to $135.

Price Target

Reiteration

Analyst Ratings

Piper Sandler Reiterates Neutral on Biogen, Lowers Price Target to $135

Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights
Collaboration broadens Biogen's rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases
Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027
Stoke to receive $165M upfront, shared development costs and is eligible to receive up to $385M in milestones as well as royalties
CAMBRIDGE, Mass. and BEDFORD, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=rXVM9fJMUxzxRp-GexgOx6lwmA0kqoJHB3Ku8rd2wQJYTzKns_jqnkUN2rTj76UbazIktVNfveZf08nTV-eQ6w==">Biogen Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) and <a href="https://www.globenewswire.com/Tracker?data=bQ_24w8H-E2VVXgF2Xw91le8MDxJhIKKX0DvbH1YPsW-vXeoxFIpNwEyhPQm8lHIpVoCRoWrUOEv2LOQQmESSB4rVfC9A-9t2vUK_J4NbZwvtbBsPEZ9dCrFqkkvVTeL">Stoke Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) today announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a global Phase 3 registrational study of zorevunersen (EMPEROR) following successful alignment with regulatory agencies in the United States, Europe, and Japan. The study is on track to initiate in the second quarter of 2025, with a pivotal data readout expected in the second half of 2027, which is anticipated to support global regulatory filings.
Significant unmet treatment needs remain for patients with Dravet syndrome, a severe, genetic developmental and epileptic encephalopathy characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments. There are no approved disease-modifying therapies for Dravet syndrome, which is difficult to treat and has a poor long-term prognosis. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S., UK, EU-4 and Japan.1

Biogen And Stoke Therapeutics Enter Into Collaboration To Develop And Commercialize Zorevunersen For The Treatment Of Dravet Syndrome, A Rare Genetic Epilepsy Associated With Refractory Seizures And Neurodevelopmental Impairments; Stoke Retains Zorevunersen Rights In US, Canada, Mexico; Biogen Gains Global Rights; Stoke To Receive $165M Upfront, Up To $385M In Milestones; EMPEROR Phase 3 Study To Begin Q2 2025 With Results In H2 2027

On Wednesday,&nbsp;Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.35</a>.
The company&nbsp;reported&nbsp;sales of&nbsp;$2.46 billion, up 2% year over year on constant currency and 3% on a reported basis, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43673992/biogen-delivers-q4-beat-analyst-focuses-on-leqembi-expansion-2025-outlook" rel="noreferrer noopener">consensus of $2.40 billion</a>.
Needham analyst Ami Fadia expects challenges in the multiple sclerosis segment, as growth from key product launches isn&#8217;t enough to make up for declines.
While Leqembi sales performed well outside the U.S. and Skyclarys is set to grow internationally, Medicare Part D changes will hit its U.S. sales, reducing revenue by about $15–$30 million. The analyst expects it will take time for the business to regain momentum.
As a result, revenue projections for 2025 have been lowered, affecting longer-term estimates. The firm remains cautious, awaiting clearer signs of growth from the company&#8217;s pipeline, existing drugs, or business development. Needham <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings" target="_blank" rel="noreferrer noopener">maintains a Hold rating</a>.
HC Wainwright analyst Ananda Ghosh expects lecanemab&#8217;s growth to gain momentum once blood-based biomarkers, which could be approved in the second half of 2025, help reduce challenges related to MRI scans.
Given the guidance of a year-over-year revenue decline, the HC Wainwright analyst re-evaluates revenue estimates, given the near-term headwinds. Thus, the price target is reduced to $241 from $300, maintaining the Buy rating.
Oppenheimer analyst Jay Olson expects Leqembi and Skyclarys to boost long-term revenue, though it may take time for that growth to materialize. He also sees the Fit-for-Growth initiatives helping improve operating margins over time.
With an Outperform rating and $255 price target, Olson is optimistic about the competitive landscape, noting that evidence favors ongoing treatment rather than a fixed duration. As a result, Oppenheimer anticipates some patients may switch from donanemab to Leqembi, especially with the availability of a subcutaneous (subQ) version.
RBC Capital Markets says Biogen has effectively streamlined its research and development priorities and optimized expenses, as reflected in its fourth-quarter results and 2025 guidance, leading to a stronger core business structure.
Analyst Brian Abrahams believes Biogen&#8217;s stock is undervalued compared to its actual business fundamentals. He suggests that progress with Leqembi&#8217;s subcutaneous version or EU approvals, a pipeline success, or favorable deals could help shift investor sentiment and narrow this gap.
RBC Capital has lowered the price target to $225 from $231 with an Outperform rating.
Truist writes Leqembi&#8217;s growth remains the main focus for both Biogen and investors. While new formulations and blood-based diagnostics may support growth in 2025, they don&#8217;t anticipate significant breakthroughs.
Analyst Srikripa Devarakonda maintains the Buy rating while lowering the price target from $220 to $210.
Price Action: BIIB stock is up 4.06% at $138.85 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43696324/sap-partners-with-databricks-to-launch-business-data-cloud" target="_blank" rel="noreferrer noopener">SAP Unleashes Business Data Cloud With Smarter AI Insights: Details</a></li>
</ul>
Photo: Tada Images/Shutterstock.com

Analyst Color

Equities

Trading Ideas

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

Scotiabank analyst George Farmer maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Sector Outperform and lowers the price target from $244 to $224.

Scotiabank Maintains Sector Outperform on Biogen, Lowers Price Target to $224

BMO Capital analyst Evan Seigerman maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Market Perform and lowers the price target from $156 to $139.

BMO Capital Maintains Market Perform on Biogen, Lowers Price Target to $139

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Equal-Weight and lowers the price target from $192 to $157.

Morgan Stanley Maintains Equal-Weight on Biogen, Lowers Price Target to $157

Goldman Sachs analyst Salveen Richter maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $281 to $245.

Goldman Sachs Maintains Buy on Biogen, Lowers Price Target to $245

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and lowers the price target from $231 to $225.

RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $225

Citigroup analyst Geoff Meacham maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Neutral and lowers the price target from $160 to $145.

Citigroup Maintains Neutral on Biogen, Lowers Price Target to $145

Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Equal-Weight and lowers the price target from $165 to $140.

Wells Fargo Maintains Equal-Weight on Biogen, Lowers Price Target to $140

Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported better-than-expected earnings for its fourth <a href="https://www.benzinga.com/quote/biib/earnings">quarter on Wednesday</a>.
The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.
Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.
Biogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.
Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.
Biogen shares fell 4.3% to close at $133.43 on Wednesday.
These analysts made changes to their price targets on Biogen following earnings announcement.
<ul>
<li>Canaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.</li>
<li>Truist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.</li>
<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.</li>
</ul>
Considering buying BIIB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="569" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png" alt="" class="wp-image-781120" style="width:574px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121.png 1135w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Biogen Analysts Lower Their Forecasts After Q4 Results

HC Wainwright &amp; Co. analyst Andrew Fein maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $300 to $241.

HC Wainwright & Co. Maintains Buy on Biogen, Lowers Price Target to $241

Truist Securities analyst Srikripa Devarakonda maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $220 to $210.

Truist Securities Maintains Buy on Biogen, Lowers Price Target to $210

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $194.7, with a high estimate of $270.00 and a low estimate of $138.00. A 23.68% drop is evident in the current average compared to the previous average price target of $255.11. 
<img src="https://www.benzinga.com/files/images/story/2025/1739451635_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Biogen's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$265.00</td>
<td>$298.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$138.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$164.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$178.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$180.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$207.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Biogen's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Biogen's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>Unveiling the Story Behind Biogen</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>Breaking Down Biogen's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Biogen's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -2.55% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.76%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Biogen's ROE stands out, surpassing industry averages. With an impressive ROE of 2.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Biogen's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.41%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.41.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 10 Analyst Projections For Biogen

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $298 to $265.

Canaccord Genuity Maintains Buy on Biogen, Lowers Price Target to $265

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Hold to Hold.

Needham Reiterates Hold on Biogento Hold

On Wednesday,&nbsp;Biogen Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)&nbsp;reported fourth-quarter adjusted EPS of $3.44, up 17%, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.35</a>.
The company reported sales of $2.46 billion, up 2% year over year on constant currency and 3% on a reported basis, beating the <a href="https://www.benzinga.com/general/biotech/25/02/43659412/biogen-warns-lower-2025-revenue-inks-rd-funding-pact-with-royalty-pharma-for-late-stage-lupus-asset" target="_blank" rel="noreferrer noopener">consensus of $2.40 billion</a>.
As part of ongoing pipeline prioritization efforts, Biogen has decided to discontinue further development of BIIB113 in early Alzheimer&#8217;s disease, BIIB094 in early Parkinson&#8217;s disease, BIIB101 in multiple system atrophy, and BIIB143 (cemdomespib) in diabetic peripheral neuropathic pain.
Biogen forecasts a full-year 2025 adjusted EPS of $15.25-$16.25&nbsp;versus a consensus of $16.34.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42397286/biogen-downgraded-on-pipeline-setbacks-and-leqembi-sales-slowdown" rel="noreferrer noopener">Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown</a>
Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.
Goldman Sachs analyst Salveen Richter notes that Biogen&#8217;s management expects to remain disciplined with regard to capital allocation, pointing to an interest in early-to-mid-stage deals in immunology, <a target="_blank" href="https://www.benzinga.com/quote/BIIB/analyst-ratings" rel="noreferrer noopener">rare diseases, and neurology</a>.
The analyst notes that while Goldman Sachs is mainly focused on Zurzuvae and Skyclarys, it is also watching for declines in the multiple sclerosis portfolio and Spinraza business. The main priority is how the company plans to counteract these losses through new product launches and business development.
Investors were especially concerned about the FY25 outlook compared to market expectations, particularly for Leqembi, and the company&#8217;s plans for mergers, acquisitions, and pipeline growth.
The analyst notes that for Leqembi&#8217;s rollout in early Alzheimer&#8217;s, the growth of infusion centers and more doctors prescribing it are major advantages. So far, Eli Lilly&#8217;s Kisunla has had little impact.
&#8220;We continue to watch market share vs. growth dynamics, and the extent to which the IV maintenance approval, the potential approvals of subcutaneous maintenance and induction, alongside the wider availability of blood-based biomarkers will drive launch momentum in 2025+,&#8221; Goldman Sachs analyst writes.
Price Action: BIIB stock is down 4.6% at $132.90 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43667099/crypto-for-a-cause-blackbaud-teams-up-with-the-giving-block-to-supercharge-nonprofit-donations" target="_blank" rel="noreferrer noopener">Crypto For A Cause: Blackbaud Teams Up With The Giving Block To Supercharge Nonprofit Donations</a></li>
</ul>
Photo: Tada Images/Shutterstock.com

Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by <a href="https://www.benzinga.com/government/regulations/25/02/43656846/inflation-rises-more-than-expected-in-january-chills-interest-rate-cut-hopes">midday trading in New York.</a>
The S&amp;P 500 was down 0.2%, while the Nasdaq 100 was flat, both rebounding from sharp declines following the January Consumer Price Index report. Small-cap stocks underperformed, with the Russell 2000 slipping 0.8%.
The headline CPI rose 3% year over year in January, surpassing both December's 2.9% reading and economist forecasts of 2.9%. On a monthly basis, inflation increased 0.5%, outpacing expectations of 0.3% and accelerating from December's 0.4% gain. This marked the fastest monthly inflation rate since August 2023.
Core inflation, which excludes food and energy, climbed to 3.3% year over year from 3.2% in December. On a monthly basis, core CPI increased 0.4%, exceeding estimates of 0.3% and doubling December's 0.2% rise.
Treasuries and interest rate markets reacted sharply to the inflation data. Traders scaled back expectations for Federal Reserve rate cuts, now projecting only one reduction by December 2025.
Treasury yields surged, reflecting heightened investor uncertainty. The 10-year Treasury yield jumped 10 basis points to 4.64%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 1%.
Despite rising Treasury yields and a stronger dollar, gold edged up 0.2% to $2,910 per ounce. Oil prices dropped 2% after reports that Donald Trump spoke with Russian President Vladimir Putin, fueling speculation about a potential ceasefire in Ukraine.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also rebounded from earlier session losses.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,688.40</td>
<td>0.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,056.85</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,411.00</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.59</td>
<td>-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;inched 0.2% down to $603.77.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was 0.4% down to $444.41.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;flattened at $528.09.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.8% to $224.</li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.4%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.2%.</li>
</ul>
Wednesday&#8217;s Stock Movers
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped more than 4% after the electric vehicle maker tumbled 6.3% on Tuesday, reaching oversold levels and extending its losing streak to five consecutive sessions.</li>
</ul>
Stocks reacting to company earnings reports included: 
<ul>
<li>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>): up 15.7%</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>): up 4.5%</li>
<li>Edwards Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>): up 5.6%</li>
<li>América Móvil, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>): down 1.4%</li>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>): up 0.2%</li>
<li>Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>): up 0.3%</li>
<li>Southern Copper Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>): up 2.9%</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): up 6.8%</li>
<li>Zillow Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>): down 10.2%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>): up 2.2%</li>
<li>Chimera Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>): down 8.9%</li>
<li>Ryder System Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>): up 4.0%</li>
<li>Smurfit WestRock Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>): down 5.8%</li>
<li>Sonic Automotive Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>): down 2.4%</li>
<li>Alkermes Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>): up 4.1%</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>): up 1.0%</li>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>): down 4.6%</li>
<li>Blackstone Mortgage Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXMT#NYSE">BXMT</a>): up 2.8%</li>
<li>Camtek Ltd/Israel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>): up 1.5%</li>
<li>Chefs' Warehouse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>): up 13.0%</li>
<li>Diebold Nixdorf Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBD#NYSE">DBD</a>): down 3.2%</li>
<li>Dominion Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>): up 0.6%</li>
<li>Exelon Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>): up 0.4%</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43663963/record-high-egg-prices-drive-inflation-higher-in-january">Record-High Egg Prices Drive Inflation Higher In January</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Commodities

Economics

Federal Reserve

Tech

ETFs

$BTC

ALKS

AVXL

BXMT

CAMT

CHEF

SPDR Dow Jones Industrial Average ETF Trust

GILD

SCCO

SMCI

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Select Sector SPDR-Consumer Discretionary

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?

Press Releases

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen's Unsolicited Acquisition Proposal

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
02:18 PMFeb 19, 2025	PUT	$115.00	Jan 15, 2027	690	1471	450	4903	30	TRADE	BEARISH
02:16 PMFeb 19, 2025	PUT	$115.00	Jan 15, 2027	690	1001	1000	3337	30	TRADE	BEARISH

Comments

Biogen

Unusual Options Activity for

ニュース

パートナーシップ

ベンジンガ・グローバル